Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Entasis Therapeutics Holdings Inc. announced that the Top-line DATA from the Company’s Crucial Phase  3 ATTACK Trial was presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Annual Conference, April 23-26, 2022, Lisbon, Portugal.

FREMONT, CA: Dr. Alita Miller, Vice President, Microbiology, discussed the characterization of Acinetobacter baumannii-calcoaceticus complex (ABC) pathogens isolated from patients enrolled in the attack phase 3 trial. She also analysed the in vitro liabilities of the ABC isolates from the 183 m-MITT patients enrolled in the ATTACK study. The collection was found to be 96 percent carbapenem- and multidrug-resistant, 84 percent extensively drug-resistant, and 15 percent pan-drug resistant, according to the study's findings. Colistin was the only comparator antibiotic tested that showed more than 60 percent in vitro susceptibility. Except for Colistin, whose non-susceptibility ranged from zero percent in Latin America and China to 30 percent in Europe, susceptibility to SUL-DUR and comparators was consistent across different regions and infection types.

Few significant details on the Efficacy and safety of sulbactam-durlobactum (SUL-DUR) versus colistin therapy in patients with ABC infections have been highlighted by Dr David Altarac, MD, Chief Medical Officer in Entasis’s second oral presentation.

Following are the results from PART A of the attack study presented by Dr Altarac:

- The primary efficacy endpoint, 28-day all-cause mortality (ACM) in the carbapenem resistant Acinetobactor baumannii-calcoaceticus (CRABC) m-MITT cohort (n=125) was 19 percent and 32.3 percent for SUL-DUR versus colistin, respectively.

- Clinical cure rates at test-of-cure (TOC) were 61.9 percent and 40.3 percent for SUL-DUR versus colistin.

- Treatment-related Adverse Events were 12.1 percent (11/91) and 30.2% (26/86) in the SUL-DUR and colistin groups, respectively.

A clinical biopharmaceutical company, Entasis is focused on the discovery, development, and popularisation of novel antibacterial products to treat grave infections caused by multidrug-resistant gram-negative bacteria. Entasis' pathogen-targeted design platform targets infections caused by Acinetobacter spp., Neisseria gonorrhoeae, and gram-negative bacteria, in that order.